Australian Competition and Consumer Commission v Allergy Pathway Pty Ltd (No 2)

Link copied
Case Copied 64 min read

FEDERAL COURT OF AUSTRALIA

Australian Competition and Consumer Commission v Allergy Pathway Pty Ltd (No 2) [2011] FCA 74

Citation: Australian Competition and Consumer Commission v Allergy Pathway Pty Ltd (No 2) [2011] FCA 74
Parties: AUSTRALIAN COMPETITION AND CONSUMER COMMISSION v ALLERGY PATHWAY PTY LTD (FORMERLY ADVANCED ALLERGY ELIMINATION PTY LTD) and PAUL FREDERICK KEIR
File number: VID 361 of 2009
Judges: FINKELSTEIN J
Date of judgment: 10 February 2011
Catchwords: CONTEMPT OF COURT – civil contempt – breach of undertaking not to publish or cause to be published – whether statements posted on the respondent’s Facebook and Twitter pages by others constitutes publication by the respondent – appropriate penalty
Legislation:

Federal Court of Australia Act 1976 (Cth), s 31

Judiciary Act 1903 (Cth), s 24

Cases cited: Australian Competition and Consumer Commission v Allergy Pathway Pty Ltd [2009] FCA 960
Australian Meat Industry Employees Union v Mudginberri Station Pty Ltd (1986) 161 CLR 98
Biba Ltd v Stratford Investments Ltd [1973] Ch 281
Bunt v Tilley [2007] 1 WLR 1243
Byrne v Deane [1937] KB 818
Godfrey v Demon Internet Ltd [2001] QB 201
Hebditch v McIlwaine [1894] 2 QB 54
Lee v Wilson (1934) 51 CLR 276
Louis Vuitton Malletier SA v Design Elegance Pty Ltd (2006) 149 FCR 494
McLeod v St Aubyn [1899] AC 549
R v Griffiths; Ex parte Attorney General [1957] 2 QB 192
R v Thomson Newspapers Ltd; Ex parte Attorney-General [1968] 1 WLR 1
Thompson v Australian Capital Television Pty Ltd (1996) 186 CLR 574
Urbanchich v Drummoyne Municipal Council (1991) Aust Torts Reports ¶81-127 (NSW SC)
Witham v Holloway (1995) 183 CLR 525
Date of hearing: 19 October 2010
Date of last submissions: Applicant’s supplementary submissions:  27 October 2010
Place: Melbourne
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 40
Counsel for the Applicant: Mr J Moore
Solicitor for the Applicant: Corrs Chambers Westgarth
Counsel for the Respondents: Mr W V McManus
Solicitor for the Respondents: Harris Freidman

IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

GENERAL DIVISION

VID 361 of 2009

BETWEEN:

AUSTRALIAN COMPETITION AND CONSUMER COMMISSION
Applicant

AND:

ALLERGY PATHWAY PTY LTD (FORMERLY ADVANCED ALLERGY ELIMINATION PTY LTD)
First Respondent

PAUL FREDERICK KEIR
Second Respondent

JUDGE:

FINKELSTEIN J

DATE OF ORDER:

10 FEBRUARY 2011

WHERE MADE:

MELBOURNE

THE COURT DECLARES THAT:

1.The first respondent is guilty of contempt by reason of its breaches of the undertaking it gave to the Federal Court of Australia on 27 August 2009.

2.The second respondent is guilty of contempt by reason of his breaches of the undertaking he gave to the Federal Court of Australia on 27 August 2009.

THE COURT ORDERS THAT:

For the purposes of these orders, the following definitions apply:

(a)“allergy” or “allergies” means a physical hypersensitivity in an individual to certain substances which are normally harmless such as pollen, foods and fruits and which produces an allergic reaction in that individual and which may be initiated by:

(i)        contact with the skin;

(ii)       inhalation;

(iii)      ingestion;…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Australian Competition and Consumer Commission v Allergy Pat... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2011] FCA 74
Decision Date

CaseChat Overview and Summary

The Australian Competition and Consumer Commission (ACCC) initiated proceedings against Allergy Pathway Pty Ltd (Allergy Pathway) and its director, Mr Keir, for contempt, alleging that they had breached undertakings given to the Court. The undertakings had required them not to make specific representations about their allergy testing and treatment services. The representations included claims that Allergy Pathway could accurately test for allergens, cure or eliminate allergies, and that their treatment was safe and low-risk. The ACCC argued that these statements had been published on Allergy Pathway's Facebook and Twitter pages, constituting a breach of the undertakings.

The primary legal issues the Court had to decide were whether the statements posted on Allergy Pathway's social media platforms by others constituted publication by the respondents, and what appropriate penalty should be imposed. The Court found that the statements did constitute publication by the respondents because they had control over their social media accounts and had not taken steps to prevent the publication of these claims. The Court also considered the nature and extent of the breach, the respondents' conduct, and the need for deterrence and vindication of the Court's authority.

The Court imposed a fine of $7500 on each respondent and ordered them to be restrained from making the specified representations for three years. Additionally, Allergy Pathway was required to publish corrective notices at its clinics, on its websites and social media pages, and to distribute corrective letters to its customers. The Court also ordered that the respondents pay the ACCC's costs of the proceedings on an indemnity basis. The Court's decision emphasised the importance of adhering to court undertakings and the consequences of non-compliance.

Orders

Orders of the court

For the purposes of these orders, the following definitions apply:

(a) “allergy” or “allergies” means a physical hypersensitivity in an individual to certain substances which are normally harmless such as pollen, foods and fruits and which produces an allergic reaction in that individual and which may be initiated by:

(i) contact with the skin;

(ii) inhalation;

(iii) ingestion; or

(iv) injection;

(b) “allergen” means a substance which elicits an allergic reaction in an individual; and

(c) “allergic reaction” means an immunological process of specific allergen recognition and pathological response.

Fines

3. The first respondent be fined in the sum of $7500, such sum to be paid within 90 days.

4. The second respondent be fined $7500, such sum to be paid within 90 days.

Injunctions and undertakings

5. The undertaking given by the first respondent on 27 August 2009 be and it hereby is discharged.

6. The undertaking given by the second respondent on 27 August 2009 be and it hereby is discharged.

7. The first respondent be and it hereby is restrained for a period of three years, whether by itself, its directors, servants, agents or otherwise, in trade or commerce, from making, publishing or causing to be made or published in any form whatsoever, representations to the effect that:

(a) it can accurately test for and identify an allergen for a person and/or a substance which causes a person’s allergic reaction;

(b) it can cure or eliminate, or successfully treat, any allergies or any allergic reactions;

(c) its treatment for a person’s allergies or allergic reactions is safe and/or low risk;

(d) after its treatment of a person’s allergies or allergic reactions it is safe for that person to have contact with the allergen to which the person had an allergic reaction;

and/or any representations to the same or similar purport or effect.

8. The second respondent be and he hereby is restrained for a period of three years from being directly or indirectly knowingly concerned in, or a party to, the conduct of the first respondent or any other corporation whereby the first respondent or the other corporation whether by itself, its directors, servants, agents or otherwise, in trade or commerce, makes any representation to the effect that:

(a) it can accurately test for and identify an allergen for a person and/or a substance which causes a person’s allergic reaction;

(b) it can cure or eliminate, or successfully treat, any allergies or any allergic reactions;

(c) its treatment for a person’s allergies or allergic reactions is safe and/or low risk;

(d) after its treatment of a person’s allergies or allergic reactions it is safe for that person to have contact with the allergen to which the person had an allergic reaction;

and/or any representations to the same or similar purport or effect.

Corrective advertising

9. Within 14 days the first respondent, at its own expense, publish a notice in the terms and form of Annexure 1 to these orders, which notice is to be affixed on the front counter and/or the point of sale at each of the clinics operated by the first respondent for a continuous period of 90 days and in a manner such that the notice is not obscured.

10. Within 21 days the first respondent, at its own expense, cause a notice in the terms and form of Annexure 2 to these orders to be published on all websites and Twitter and Facebook pages which are owned, operated, controlled or maintained by or on behalf of the first respondent for a continuous period of 90 days and ensure that:

(a) the notice is viewable by clicking a ‘click-through’ icon located on the websites and Facebook and Twitter pages;

(b) the ‘click-through’ icon is located at the top of the homepage of the websites and Facebook and Twitter pages;

(c) the ‘click-through’ icon contains the words “False and Misleading Conduct and Contempt of Court by Allergy Pathway – Corrective Notice Ordered by Federal Court of Australia” prominently in red text on a black background and the words “click here”; and

(d) the notice occupies the entire page that is accessed via the “click-through” icon referred to above.

11. Within 21 days the first respondent, at its own expense, publish and distribute (whether electronically or otherwise) a letter in the terms and form of Annexure 3 to these orders to all persons who are the first respondent’s customers at the date of this order or who were customers of the first respondent during the period 27 July 2010 to the date of this order.

Costs

12. The first and second respondents pay the applicant’s costs of and incidental to the notice of motion filed 23 September 2010 on an indemnity basis.

Note:

Background

Background to the litigation

The applicant, the Australian Competition and Consumer Commission (ACCC), moves to punish the first respondent, Allergy Pathway Pty Ltd, and its sole director, the second respondent, Mr Keir, for contempt for having breached undertakings given to the Court on 27 August 2009. Background Allergy Pathway operates clinics for the diagnosis and treatment of allergies. The methods it uses for testing for allergies include a “muscle strength indicator” technique. Its treatment methods include a technique based on “positive and negative conditioning”. The means by which Allergy Pathway provides information about its services include posts on its website, Facebook and Twitter pages. It also advertises its services on the radio, in newspapers and in brochures distributed to clients, prospective clients and other interested persons. In early 2009 the ACCC brought an action against the respondents alleging that Allergy Pathway had contravened ss 52, 53(aa), 53(c) and 55A of the Trade Practices Act 1974 (Cth) (TPA). Those sections proscribe misleading or deceptive conduct, falsely representing that services are of a particular standard or quality, representing that services have benefits which they do not have, and engaging in conduct that is liable to mislead the public. It was alleged that Allergy Pathway had in a variety of publications falsely represented that (a) it could test for allergens; (b) it could cure or eliminate virtually all allergies or allergic reactions; (c) it could successfully treat a person’s allergies or allergic reactions; (d) its treatment of persons with allergies was safe and/or low risk; and (e) it was safe to have contact with a substance or allergen to which the person had an adverse reaction after Allergy Pathway’s treatment. It was also alleged that Mr Keir was “involved” in Allergy Pathway’s contraventions within the meaning of s 75B of the TPA. To make good its claim the ACCC tendered a report by Professor Douglass, the Head of the Allergy Asthma and Clinical Immunology Service at the Alfred Hospital. In that report Professor Douglass made the following general observations which are relevant to this application:Whilst there are proven methods of successful desensitization of individuals with allergic disease by incremental exposure to allergens, known as desensitization or ‘immunotherapy’, these methods do entail the risk of inducing a generalized allergic reaction and have not been shown to be successful in general medical practice with respect to food allergies. In the conventional medical literature, fatalities have been reported due to immunotherapy for both inhalant and food allergies. The statement that patients with true allergies can initiate contact with the substance that had previously caused the allergic reaction will, in my opinion if followed, expose some individuals to the risk of severe allergic reaction or even death. …Allergen immunotherapy is the only form of treatment which can alter the natural history and immunological parameters of allergic disease. By this I mean that the natural progression of allergic diseases appear to be altered by the administration of allergen immunotherapy. For example there is good evidence that the risk of severe allergic reactions to insect stings can be reduced by immunotherapy. …The scientific concept of allergens, their properties and identification is not consistent with the AAE statement ‘Successful elimination of allergies/sensitivities may require clearing of preliminary allergens first. If components of allergens are not cleared the items containing those compounds will remain allergenic.’ …Medically valid treatments for allergy include drug treatments and allergent specific therapies such as allergen immunotherapy. The use of these treatments is described in evidence-based guidelines such as the ARIA consensus document (Allergic Rhinitis and its Impact on Asthma), the Global Initiative in Asthma (GINA) consensus document and guidelines on immunotherapy. During the course of my practice, I have not been made aware of a medically validated therapeutic process of ‘positive conditioning’ or ‘negative conditioning’ with regard to allergies. I am therefore unaware of ‘positive conditioning’ and ‘negative conditioning’ as an effective form of allergy treatment. I am aware that ‘positive conditioning’ and ‘negative treatment’ does not form part of the body of authoritative treatment guidelines for allergic diseases. In my opinion I do not believe the scientific literature has information to support ‘positive conditioning’ or ‘negative conditioning’ treatments to cure or eliminate allergies. …I am not aware of the muscle strength testing as a medically validated test for allergy, nor is it recommended in international consensus treatment and diagnosis guidelines. …As a clinical practitioner in the field of allergy for over 18 years I am not aware of acupressure or muscle testing being used in Australia or internationally to effectively treat allergies by medical practitioners. …The categories of allergens claimed to be treated by AAE include contactant, inhalant, ingestant and injectant. I am not aware of effective strategies of allergen immunotherapy for contactant allergies. I have stated previously the difficulties in treating ingestant allergies. I am unable to verify the statements claiming cure or improvement of allergies through the Allergy Elimination Technique. I do not believe there is published scientific evidence to support these claims. …[I]ndividuals with true allergic disease could be harmed by this treatment. Many of the symptoms claimed to be relieved in the AAE publicity brochures, such as irritable bowel syndrome, diarrhoea and attention deficit disorder are unlikely due to an allergic process and therefore unlikely to have an immunological basis. However the brochures do state that ‘ingestant’ allergies can be eliminated. I take this to mean food allergies. At the current time to my knowledge, there is no safe, scientifically-based treatment for food allergies. …I am concerned by claims that AAE can treat wheezing and asthma. In my own and international experience, there is currently no known cure for asthma, which still carries a very substantial burden of illness which includes mortality. (emphasis added)

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established